肝吸蟲治療市場機會、成長要素、產業趨勢分析及2026-2035年預測。

2025 年全球肝吸蟲病治療市場價值為 6.427 億美元，預計到 2035 年將以 5% 的複合年成長率成長至 10 億美元。

受全球人類和動物寄生蟲感染疾病率上升的推動，該市場正經歷穩定成長。隨著人們對早期診斷和改善治療效果的重視程度不斷提高，對有效治療方案的需求也不斷成長。包括分子檢測在內的診斷技術的進步顯著提升了早期檢測能力，從而能夠及時干預並改善疾病管理。此外，對醫療基礎設施和藥物研發活動的投入增加，也促進了先進治療方法的開發和治療方案的改進。同時，高風險地區預防醫學實踐的推廣也進一步推動了市場成長。在藥物研發持續創新、公眾意識不斷提高以及獸醫學與人類醫學融合日益緊密的背景下，整個產業的前景依然光明。

肝吸蟲病的治療涉及內科和獸醫學方法，旨在診斷和根除由肝吸蟲引起的、影響肝臟及相關器官的寄生蟲感染疾病。這些感染疾病若不及時治療，可能導致嚴重的健康併發症，並影響人類和牲畜。治療策略通常包括抗寄生蟲藥物、支持性護理以及預防措施，以控制感染傳播和緩解相關症狀。該市場的特點是存在多家成熟的製藥公司，致力於開發有效的治療方法並擴大全球治療方案的可及性。

預計到2025年，三氯苯達唑類藥物的銷售額將達到2.664億美元。其市場主導地位得益於其在治療肝吸蟲感染方面的顯著療效，尤其是在該疾病高發生率地區。該藥物卓越的安全性和高效性使其在人類和獸醫領域中廣泛應用。其價格適中進一步提高了藥物的可近性，尤其是在醫療資源有限的地區，使其成為大規模用藥的首選治療方案。

預計到2025年，片劑將佔據41.4%的市場。這主要歸功於其便捷的服用方式。片劑因其穩定性好、保存期限長、儲存要求低等優點而廣受歡迎，使其能夠跨越不同地域進行分銷。製劑技術的進步提高了藥物的吸收率和療效，從而改善了治療效果。多個地區完善的法規結構進一步加快了片劑治療方法的核准和上市，促進了其在全球市場的普及。

預計到2025年，北美肝吸蟲病治療市場規模將達2.618億美元。這反映了該地區穩定的市場需求，並得益於其健全的醫療保健和獸醫體系。高度發展的畜牧業極大地促進了對有效寄生蟲控制措施的需求，以保障生產力和動物健康。藥物研發的不斷進步和成熟治療方法的普及進一步推動了市場成長。醫療保健專業人員和畜牧業管理者意識提升也促進了常規預防和治療性介入的實施，從而鞏固了區域市場的穩定性。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 肝吸蟲感染疾病發生率增加
    • 診斷技術的進步
    • 畜牧業發展
    • 有效治療的可近性
  • 產業潛在風險與挑戰
    • 與替代治療方法的競爭
    • 對常用驅蟲藥的抗藥性
  • 市場機遇
    • 獸醫預防醫學和畜群管理解決方案的發展
    • 拓展新興市場與低度開發市場
• 成長潛力分析
• 監理情勢（基於初步調查）
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 未來市場趨勢
• 價格分析（基於初步調查）
• 管道分析
• 人工智慧和生成式人工智慧對市場的影響
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依藥物類型分類，2022-2035年

• 三氯苯達唑
• 普拉齊坎特
• 比特約諾爾
• 阿苯達唑
• 硝唑尼德
• 其他藥物類型

第6章 市場估算與預測：依製劑類型分類，2022-2035年

• 藥片
• 注射藥物
• 口服懸浮液

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 人類
• 動物

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院
• 診所
• 動物醫院
• 其他最終用戶

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AdvaCare Pharma
• Bayer Healthcare
• GlaxoSmithKline
• Lupin Pharma
• Merck
• Novartis
• Par Pharmaceutical
• Pfizer
• Schering Corporation
• Vetoquinol
• Virbac
• Zoetis

The Global Liver Fluke Treatment Market was valued at USD 642.7 million in 2025 and is estimated to grow at a CAGR of 5% to reach USD 1 billion by 2035.

The market is witnessing steady growth driven by the rising incidence of parasitic infections affecting both human and animal populations across various regions. Increasing emphasis on early diagnosis and improved treatment outcomes is strengthening demand for effective therapeutic solutions. Advancements in diagnostic technologies, including molecular-based testing methods, have significantly enhanced early detection capabilities, enabling timely intervention and improved disease management. Additionally, growing investments in healthcare infrastructure and pharmaceutical research activities are supporting the development of advanced treatment options and improved therapeutic protocols. Preventive healthcare practices are also gaining traction in high-risk regions, further contributing to market expansion. The overall industry outlook remains positive, supported by continuous innovation in drug development, increasing awareness, and stronger veterinary and human healthcare integration.

Liver fluke treatment involves medical and veterinary approaches aimed at diagnosing and eliminating parasitic infections caused by trematode organisms that affect the liver and associated organs. These infections can lead to significant health complications if left untreated, impacting both humans and livestock. Treatment strategies typically include antiparasitic medications, supportive care, and preventive measures designed to control infection spread and manage associated symptoms. The market is characterized by the presence of several established pharmaceutical companies that focus on developing effective therapeutic solutions and expanding global access to treatment options.

The triclabendazole segment generated USD 266.4 million in 2025. This dominance is supported by its proven effectiveness in treating liver fluke infections, particularly in regions where such conditions are more prevalent. The drug's strong safety profile and high therapeutic efficacy have contributed to its widespread adoption in both human and veterinary applications. Its affordability further enhances accessibility, especially in regions with limited healthcare resources, making it a preferred treatment option for large-scale use.

The tablets segment accounted for 41.4% share in 2025, driven by its practicality and ease of administration. Tablets are widely preferred due to their stability, extended shelf life, and minimal storage requirements, making them suitable for distribution across diverse geographical regions. Improvements in pharmaceutical formulation have enhanced drug absorption and effectiveness, supporting better treatment outcomes. Established regulatory frameworks across multiple regions have further facilitated the approval and availability of tablet-based therapies, strengthening their adoption in global markets.

North America Liver Fluke Treatment Market was valued at USD 261.8 million in 2025, reflecting steady regional demand supported by strong healthcare and veterinary systems. The presence of a well-developed livestock industry significantly contributes to the need for effective parasite control measures to safeguard productivity and animal health. Continuous advancements in pharmaceutical research and the availability of established treatment options further support market growth. Increased awareness among healthcare professionals and livestock managers has also encouraged routine preventive and therapeutic interventions, reinforcing regional market stability.

Key companies operating in the Global Liver Fluke Treatment Market include Merck, Bayer Healthcare, Novartis, Virbac, GlaxoSmithKline, Pfizer, Vetoquinol, AdvaCare Pharma, Lupin Pharma, Schering Corporation, Par Pharmaceutical, and Zoetis. Companies in the Liver Fluke Treatment Market are focusing on research-driven innovation, portfolio expansion, and strategic partnerships to strengthen their market position. Continuous investment in drug development is enabling the introduction of more effective and safer therapeutic solutions. Firms are expanding their geographic reach through strengthened distribution networks to improve product accessibility across both developed and emerging regions. Collaboration with veterinary and healthcare institutions is supporting better awareness and adoption of treatment protocols. Additionally, companies are emphasizing affordability and accessibility to address demand in resource-constrained regions. Ongoing advancements in diagnostic and treatment technologies, combined with targeted marketing strategies, are further enhancing competitive positioning and long-term market sustainability.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Business trends
  • 2.2.2 Regional trends
  • 2.2.3 Drug type trends
  • 2.2.4 Formulation type trends
  • 2.2.5 Application trends
  • 2.2.6 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of liver fluke infections
    • 3.2.1.2 Advancements in diagnostic techniques
    • 3.2.1.3 Growing livestock industry
    • 3.2.1.4 Availability of effective therapeutics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Competition from alternative treatments
    • 3.2.2.2 Resistance to commonly used anthelmintic drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growth in veterinary preventive care and herd management solutions
    • 3.2.3.2 Expansion in emerging and underserved markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Future market trends
• 3.6 Pricing analysis (Driven by primary research)
• 3.7 Pipeline analysis
• 3.8 Impact of AI and Generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Triclabendazole
• 5.3 Praziquantel
• 5.4 Bithionol
• 5.5 Albendazole
• 5.6 Nitazoxanide
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Formulation Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Tablets
• 6.3 Injections
• 6.4 Oral suspension

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Human
• 7.3 Animals

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Veterinary facilities
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AdvaCare Pharma
• 10.2 Bayer Healthcare
• 10.3 GlaxoSmithKline
• 10.4 Lupin Pharma
• 10.5 Merck
• 10.6 Novartis
• 10.7 Par Pharmaceutical
• 10.8 Pfizer
• 10.9 Schering Corporation
• 10.10 Vetoquinol
• 10.11 Virbac
• 10.12 Zoetis